Ni-C@MOF-Apt microspheres with enzyme activity and photodynamic properties for capture and clearance of MCF-7 cells
Microchimica Acta · 2026
DOI: 10.1007/s00604-026-08414-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microchimica Acta, 2026. Verfasst von Qilong Hao und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Product Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, P. R. China. Hauptthemen laut MEDLINE: Nickel, Neoplastic Cells, Circulating, Photosensitizing Agents, Metal-Organic Frameworks. Die Arbeit nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, The Major Science and Technology Project of Gansu Province.
Abstract (Originalsprache)
Circulating tumor cells (CTCs) carry a migration risk, prone to forming metastatic foci and exacerbating the disease. Therefore, it is of great importance to improve the capture efficiency and killing effect of CTCs. First, Ni-doped covalent organic framework (Ni-COF) is used as a precursor for calcination at 900 °C, which reduces Ni2+ to magnetic Ni nanoparticles, and COF evolve into carbon nanospheres exhibiting enzyme activity (Ni-C-900). Then, with the photosensitizer meso-Tetrakis (4-carboxyphenyl) porphyrin (TCPP) as the first ligand and (2,5-dicarboxyphenyl) boronic acid (DCBA) as the second ligand, a metal-organic framework shell is in-situ grown on the surface of Ni-C-900 to obtain Ni-C@MOF. Finally, the aptamers are orderly linked via DCBA ligands to obtain Ni-C@MOF-Apt microspheres. Ni-C@MOF-Apt exhibits excellent targeting towards MCF-7 cancer cells, with a capture efficiency of 82.6% in whole-blood samples (1000 cells per milliliter), and the capture efficiency can still be maintained at 71% within a relatively low cell-concentration range (50 cells per milliliter). In addition, under weakly acidic conditions, Ni-C@MOF-Apt exhibits peroxidase (POD) and oxidase (OXD) activities, which can generate reactive oxygen species (ROS) to eliminate MCF-7 cells in synergy with photodynamic effects. This strategy combines nanozyme activity with photodynamic effects and improves the killing efficacy against MCF-7 cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Product Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, P. R. China.
- CAS Key Laboratory of Chemistry of Northwestern Plant Resources, Key Laboratory for Natural Medicines of Gansu Province, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences (CAS), Lanzhou, 730000, PR Chin…
- University of Chinese Academy of Sciences, Beijing, 100049, PR China.
- Department of Cardiology, Gansu Clinical Medical Research Center for Cardiovascular Diseases, The First Hospital of Lanzhou University, The First Clinical Medical College of Lanzhou University, Lanzhou, 730000, China.
- State Key Laboratory of Natural Product Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, P. R. China. zhanghx@lzu.edu.cn.
Förderung
- National Natural Science Foundation of China
- The Major Science and Technology Project of Gansu Province
Zitieren
APA
Hao, Q., Yang, Y., Mu, S., Liu, X., Shi, Y., & Zhang, H. (2026). Ni-C@MOF-Apt microspheres with enzyme activity and photodynamic properties for capture and clearance of MCF-7 cells. Microchimica Acta. https://doi.org/10.1007/s00604-026-08414-8
Vancouver
Hao Q, Yang Y, Mu S, Liu X, Shi Y, Zhang H. Ni-C@MOF-Apt microspheres with enzyme activity and photodynamic properties for capture and clearance of MCF-7 cells. Microchimica Acta. 2026. doi:10.1007/s00604-026-08414-8
BibTeX
@article{Hao2026,
author = {Hao, Qilong and Yang, Yi and Mu, Shuai and Liu, Xiaoyan and Shi, Yanping and Zhang, Haixia},
title = {Ni-C@MOF-Apt microspheres with enzyme activity and photodynamic properties for capture and clearance of MCF-7 cells},
journal = {Microchimica Acta},
year = {2026},
doi = {10.1007/s00604-026-08414-8}
}
EUVIMED